Common mutations in exon 10 of RET proto-oncogene in patients with medullar thyroid carcinoma
Trauma Monthly: 16 (2); 73-78 Article Type: Research Article
S, Zarif Yegane
M, Sheykhol Eslami
S, Hoghoughi Rad
F, et al. Common mutations in exon 10 of RET proto-oncogene in patients with medullar thyroid carcinoma,
Online ahead of Print
Aims: Medullary thyroid carcinoma accounts for 5-10% of total types of thyroid cancers. An important role of mutations in the RET proto-oncogene in MTC has been well identified. The purpose of this study was to determine the prevalence of seven common germ-line mutations of the RET proto-oncogene in exon 10 in Iranian MTC patients.
Methods: This descriptive study was performed in year 2009-2010. The study population was 217 MTC patients and their first-degree relatives who were selected by simple sampling method. Genomic DNA content of peripheral blood was extracted according to standard salting out/Proteinase K method. Mutation detection in RET proto-oncogene in exon 10 was assessed through PCR-RFLP method.
Results: In 217 individuals (Female: Male 1.4:1, mean age 33.4±15.8 years), 9 mutations were identified at codons 618 (7 mutations) and 620 (2 mutations) in RET proto-oncogene exon 10. The most common amino-acid change was Cys618Phe. In addition, no mutation was found in codon 611.
Conclusion: The mutations frequency of the RET proto-oncogene in exon 10 is 6% in the studied population. Accordingly, existence of the common mutations in the RET proto-oncogene in all MTC patients and their families is recommended particularly in other exons (11, 12, 13, 14, 15, 16) with a direct DNA sequencing method.
© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.